Bibliography
- KNOCH M, KELLER M: The customised electronic nebuliser: a new category of liquid aerosol drug delivery system. Expert Opin. Drug Deliv. (2005) 2(2):370-390.
- MAEHARA N, UEHA S, MORI E: Influence of the vibrating system of a multipinhole-plate ultrasonic nebuliser on its performance. Rev. Sci. Instrum. (1986) 57:2870-2876.
- STANGL R: Quality control of inhalers for clinical studies. Proceedings of the Drug Delivery to the Lungs XIV, London, UK (2003):168-171.
- SEEMANN S, WEINSTEIN L: Satisfying CDRH and FDA´s 510(k) demands for device reliability with a complex electromechanical device: eFlow®. Respiratory Drug Delivery X, Boca Raton, FL, USA (2006):279-286.
- ADACHI YS, ITAZAWA T, NAKABAYASHI M et al.: Safety and usefulness of a novel eMotion™ electric mesh nebuliser in children with asthma. Allergol. Intern. (2006) 55:167-171.
- KELLER M, BUCHOLSKI A, SEEMANN S, SCHMITT A, KNOCH M: Reduction in nebulisation time of aqueous drug solutions by the eFlow® rapid in comparison to a jet nebuliser to improve patient convenience and compliance. Eur. Respir. J. (2005) 26:338s.
- STANGL R: Development of a nebuliser product platform. Proceedings of Drug Delivery to the Lungs XVI, Edinburgh, UK (2005):242-245.
- KELLER M, BUCHOLSKI A, BALCKE A, REUL K, KNOCH M: Assessment of nebulisation efficiency of a reduced glutathione-sodium solution (GSH) by a PARI LC STAR® and the eFlow® electronic nebuliser. J. Cystic Fibr. (2005) 4:30.
- SEEMANN S, SCHMITT A, WALDNER R, HUG M, KNOCH M: Improving aerosol drug delivery in CF therapy. J. Cystic Fibr. (2005) 4:31.
- SEEMANN S, WALDNER R, TSERVISTAS M, KNOCH M: A new electronic inhaler (eFlow®) to improve delivery of inhaled medications in CF patients. Am. J. Resp. Crit. Care Med. (2004) 169:A392.
- KELLER M, JAUERNIG J, LINTZ FC, KNOCH M: Nebuliser nanosuspensions: important device and formulation interactions. Respiratory Drug Delivery VIII, Tucson, AZ, USA (2002):197-206.
- SCHUSCHNIG U, KELLER M, LINTZ FC et al.: Customisation of the eFlow™ electronic inhaler to target pulmonary delivery of aztreonam formulations for the treatment of lung infections. Proceedings of Drug Delivery to the Lungs XIII, London, UK (2002):252-256.
- RATJEN F, RIETSCHEL E, KASEL D et al. : Pharmacokinetics of inhaled colestin in patients with cystic fibrosis. J. Antimicrob. Chemother. (2006) 57:306-311
- STANGL R, SEEMANN S, KNOCH M: Customizing an electronic nebuliser. J. Aerosol. Med. (2005)18:106.
- DENYER J, NIKANDER K, SMITH NJ: Adaptive Aerosol Delivery (AAD®) technology. Expert Opin. Drug Deliv. (2004) 1(1):165-176
- GELLER DE, KESSER KC: Aerosol device analysis for delivery of a novel inhaled antibiotic. J. Aerosol Med. (2005) 18:105.
- SCHUSCHNIG U, KELLER M, KNOCH M, BODEN N, KULLMANN KH: Deposition of Pulmozyme® into the sinus cavities of a human nasal cast model using PARI SINUS™. Respiratory Drug Delivery X, Boca Raton, FL, USA (2006):737-740.
- SCHUSCHNIG U, URBISCHEK M, LUBER M et al.: Comparison of delivery efficiency in a nasal cast model of fluticasone propionate suspensions and a novel solution aerosolized via the PARI VibrENT. Respiratory Drug Delivery X, Boca Raton, FL, USA (2006):741-744.
- BOEHM A, LUBER M, MENTZEL H, KNOCH M: Investigating drug delivery to the sinuses – an in vitro deposition study using a nasal cast model. Respiratory Drug Delivery X, Boca Raton, FL, USA (2006):601-604.
Patent
- PARI GMBH: US6962151 (2005).